These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19672002)

  • 1. [Assessment of protein binding].
    Enokizono J
    Nihon Yakurigaku Zasshi; 2009 Aug; 134(2):78-81. PubMed ID: 19672002
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluations of in vitro metabolism, drug-drug interactions mediated by reversible and time-dependent inhibition of CYPs, and plasma protein binding of MMB4 DMS.
    Hong SP; Lusiak BD; Burback BL; Johnson JD
    Int J Toxicol; 2013; 32(4 Suppl):75S-87S. PubMed ID: 23929452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The interaction of drug agents].
    Kukes VG; Lemina EIu; Rumiantsev AS
    Farmakol Toksikol; 1991; 54(2):82-5. PubMed ID: 1884808
    [No Abstract]   [Full Text] [Related]  

  • 4. What is the true clinical significance of plasma protein binding displacement interactions?
    Sansom LN; Evans AM
    Drug Saf; 1995 Apr; 12(4):227-33. PubMed ID: 7646820
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue factor pathway inhibitor.
    Novotny WF
    Semin Thromb Hemost; 1994; 20(1):101-8. PubMed ID: 8059228
    [No Abstract]   [Full Text] [Related]  

  • 6. [Interaction of drugs with alpha 1-acid glycoprotein (orosomucoid)].
    Bender KI; Lutsevich AN
    Farmakol Toksikol; 1987; 50(5):110-9. PubMed ID: 3319686
    [No Abstract]   [Full Text] [Related]  

  • 7. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.
    Craig WA; Welling PG
    Clin Pharmacokinet; 1977; 2(4):252-68. PubMed ID: 20259
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Protein-protein interactions, biomarkers and RNAi.
    Pagliaro L
    IDrugs; 2005 Oct; 8(10):793-5. PubMed ID: 16254793
    [No Abstract]   [Full Text] [Related]  

  • 9. Unbound total (plasma) clearance approach in interspecies pharmacokinetics correlation: theophylline-cimetidine interaction.
    Chiou WL; Choi YM
    Pharm Res; 1995 Aug; 12(8):1238-9. PubMed ID: 7494840
    [No Abstract]   [Full Text] [Related]  

  • 10. Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
    Popp BD; Hutchinson DS; Evans BA; Summers RJ
    Eur J Pharmacol; 2004 Jan; 484(2-3):323-31. PubMed ID: 14744619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs.
    Di L; Breen C; Chambers R; Eckley ST; Fricke R; Ghosh A; Harradine P; Kalvass JC; Ho S; Lee CA; Marathe P; Perkins EJ; Qian M; Tse S; Yan Z; Zamek-Gliszczynski MJ
    J Pharm Sci; 2017 Dec; 106(12):3442-3452. PubMed ID: 28927987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors causing interindividual variations of drug concentrations in blood.
    Vesell ES
    Clin Pharmacol Ther; 1974 Jul; 16(1):135-48. PubMed ID: 4602066
    [No Abstract]   [Full Text] [Related]  

  • 13. Theoretical study of interactions between muscle aldolase and F-actin: insight into different species.
    Forlemu NY; Waingeh VF; Ouporov IV; Lowe SL; Thomasson KA
    Biopolymers; 2007 Jan; 85(1):60-71. PubMed ID: 17039493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug target interaction of tubulin-binding drugs in cancer therapy.
    Sengupta S; Thomas SA
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1433-47. PubMed ID: 17069528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viewpoint: Discriminating between noncompetitive and allosteric interactions.
    Ochs RS; Ashby CR
    Synapse; 2008 Mar; 62(3):233-5. PubMed ID: 18088063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery.
    Pommier Y; Cherfils J
    Trends Pharmacol Sci; 2005 Mar; 26(3):138-45. PubMed ID: 15749159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of the interaction of neuroleptics and antidepressants with plasma proteins (review of the literature)].
    Bender KI; Kupchikov VV; Lutsevich AN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(9):116-24. PubMed ID: 1686128
    [No Abstract]   [Full Text] [Related]  

  • 18. Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: a case report.
    de Leon J; Kiesel JL; Fleming MW; Strobl B
    J Clin Psychopharmacol; 2009 Oct; 29(5):509-11. PubMed ID: 19745660
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of pH on plasma protein binding in equilibrium dialysis.
    Kochansky CJ; McMasters DR; Lu P; Koeplinger KA; Kerr HH; Shou M; Korzekwa KR
    Mol Pharm; 2008; 5(3):438-48. PubMed ID: 18345638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High performance affinity chromatography (HPAC) as a high-throughput screening tool in drug discovery to study drug-plasma protein interactions.
    Vuignier K; Guillarme D; Veuthey JL; Carrupt PA; Schappler J
    J Pharm Biomed Anal; 2013 Feb; 74():205-12. PubMed ID: 23245252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.